MITSUO MORITA, M.D.; KIICHIRO HIGASHI, M.D.; JUNICHI TAJIRI, M.D.; TATSUO SATO, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Glover and coworkers (1) have reported previously that a radioprotective agent, WR-2721 [S-2-(3-aminopropylamino) ethyl phosphorothioic acid; amifostine] lowered serum calcium and serum parathyroid hormone levels in eight patients with advanced cancers. In the July issue (2), they report the first clinical use of WR-2721 in patients with refractory hypercalcemia secondary to parathyroid cancer. After reading their first report, we administered this drug to seven patients with primary hyperparathyroidism.
The diagnosis of primary hyperparathyroidism was made on the basis of elevated serum calcium, serum immunoreactive C-terminal parathyroid hormone (iPTH), and nephrogenous cyclic adenosine monophosphate levels. Three patients had
MORITA M, HIGASHI K, TAJIRI J, et al. S-2-(3-Aminopropylamino) Ethyl Phosphorothioic Acid (WR-2721) in Primary Hyperparathyroidism. Ann Intern Med. 1985;103:961. doi: https://doi.org/10.7326/0003-4819-103-6-961_2
Download citation file:
Published: Ann Intern Med. 1985;103(6_Part_1):961.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use